We’re excited to share our latest report on gene, cell, and rna therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q4 2022 report calls out important updates and changes within the gene, cell, and rna therapy landscape.
Highlights of the report include:
Across 2022, the pipeline (preclinical to pre-registration) of gene, cell, and RNA therapies has grown by 7%
Q4 2022 specifically saw three new approvals
Dealmaking and financing by advanced molecular companies was down in Q4
When you work with our Custom Intelligence team you gain access to the deep subject matter expertise of a global network of over 400 pharma and medtech industry experts, underpinned by the market-leading data of the Citeline product suite.
Your project lead will work in collaboration with you to understand your requirements, assign dedicated consultant support, and arrange analyst research to deliver actionable solutions in accordance with your business goals.
Whether you lack available staff, want an objective perspective, or need outside expertise, our team assesses your needs and provides in-depth research, expert insights, and innovative strategies that lead to success.
Shardha Specialises in
We have received your request and we will get back to you soon.